Repligen (RGEN) Q4 2025 earnings review
Bioprocessing Recovery Confirmed; Focus Shifts to Margin Expansion
Repligen delivered a strong finish to 2025, posting 14% organic revenue growth in Q4 and beating the high end of its guidance. The bioprocessing market recovery is fully entrenched, led by double-digit gains in the Analytics and Proteins franchises. Looking to 2026, the narrative shifts from top-line recovery to profitable growth: management is guiding for a 150 basis point expansion in adjusted operating margins. This efficiency focus will allow earnings growth to outpace sales, even as the company absorbs a known 2% headwind from a major gene therapy customer.
🐂 Bull Case
After a year of investments and restructuring, the 'Fit for Growth' plan is yielding results. Adjusted operating margin hit 15.0% in Q4 and is guided to expand to 15.1-15.5% in 2026, dropping more volume directly to the bottom line.
The combination of the SoloVPE PLUS product cycle and the integration of 908 Devices' bioprocessing assets continues to drive outsized growth, cementing Repligen's position in process analytics (PAT).
🐻 Bear Case
Despite broad portfolio strength, a specific large gene therapy customer will create a 200-basis-point drag on organic growth throughout 2026. The core business must overperform to compensate.
Q4 GAAP operating margin was just 9.0% compared to 15.0% Adjusted. Heavy intangible amortization ($9.8M) and M&A integration costs ($3.3M) continue to dilute true statutory profitability.
⚖️ Verdict: 🟢
Bullish. Repligen successfully navigated the 2024 bioprocessing downturn and delivered accelerating, consistent double-digit growth in 2025. The 2026 guidance demonstrates that management's focus has successfully shifted from volume recovery to sustainable, profitable margin expansion.
Key Themes
Analytics and Proteins Lead the Charge
The 14% organic growth in Q4 was explicitly driven by the Analytics and Proteins franchises. The Analytics segment is benefiting from the multi-year upgrade cycle of the SoloVPE PLUS instrument, while Proteins successfully rebounded from a massive 2024 OEM ligand reset to become a primary growth engine again.
Specific Gene Therapy Drag Limits 2026 Upside
A known headwind from a single large gene therapy platform—which significantly reduced its orders in H2 2025—is fully baked into the 2026 outlook. Management confirmed this will act as a 2% penalty on the total company's organic growth rate. While the core portfolio is strong enough to absorb this and still guide for 9-13% organic growth, it restricts top-tier acceleration.
Expanding the High-Performance Resin Pipeline
Repligen continues to aggressively target the new modalities market with specialized products. In Q4, the company launched three new chromatography resins: AVIPure HiPer AAV9, AVIPure HiPer AAV8, and HiPer QA. This represents a critical pivot from being a hardware provider to capturing the recurring, high-margin consumables stream in the fast-growing cell and gene therapy (CGT) manufacturing space.
Direct Investment in APAC Infrastructure
Following a year where the Asia-Pacific (APAC) region consistently posted near 50% growth (excluding China), Repligen is formalizing its footprint. The company opened a new office in Singapore and expanded its presence in Japan during Q4. Shifting from distributors to a direct commercial infrastructure will improve margin capture and tighten customer relationships in this high-growth geography.
Macro Picture: FX and M&A Distort the Headline Numbers
While headline revenue growth guidance for 2026 is 10-14%, true organic growth is guided at 9-13%. The ~100 basis point spread indicates a reliance on foreign exchange tailwinds and incremental M&A contributions. Investors should monitor whether the underlying 9-13% organic engine can accelerate if the macro environment (such as U.S. tariffs impacting European supply chains) shifts.
Other KPIs
Stable and Expanding. FY25 adjusted gross margin expanded 220 basis points YoY to 52.6% (up from 50.4% in FY24). This structural improvement reflects manufacturing productivity gains ('Repligen Performance System'), better product mix (more analytics/consumables), and the normalization of resin pass-through costs.
The balance sheet remains highly defensive. Cash, cash equivalents, and marketable securities grew slightly from $757M at year-end 2024 to $768M at year-end 2025, even after absorbing the 908 Devices bioprocessing asset acquisition and continuous R&D investments ($54M GAAP R&D for the year).
Guidance
Stable. The midpoint of $825M implies ~12% reported and ~11% organic growth versus FY25. This shows a continuation of the double-digit growth trajectory established in 2025, absorbing the 2% gene therapy drag.
Accelerating. Implies a 150 basis point expansion from the 13.8% achieved in FY25. This clearly illustrates management's commitment to operating leverage as top-line growth normalizes.
Accelerating. The midpoint ($1.97) represents ~15% YoY growth over the $1.71 generated in FY25, outperforming the ~12% midpoint revenue growth and proving the effectiveness of the margin expansion strategy.
Key Questions
Gene Therapy Headwind Trajectory
The 2026 guidance includes a 200-basis-point headwind from a specific gene therapy customer. Do you expect this to bottom out in 2026, or is there a risk of further baseline degradation spilling into 2027?
M&A Pipeline and Integration
With the integration of Tantti and the 908 Devices bioprocessing portfolio largely behind us, how is the current M&A pipeline shaping up, and are valuations in the private market aligning with your disciplined framework?
Global Tariffs and Supply Chain
In early 2025, you mentioned establishing dual U.S. and European manufacturing to mitigate tariff risks. Now that we are in 2026, how much of your portfolio is fully insulated from potential U.S./EU trade friction?